Targeted lipid nanoparticles (LNPs) could deliver mRNA encoding a CAR directly to T cells inside a patient with allergic disease. The potential implications extend beyond a single allergic condition.
- Autoimmune CAR T Has Hit A Critical Moment. Are We Asking The Right Questions?
- A QMS That Anticipates Cell And Gene Therapy Quality Challenges
- Using Digital Platforms To Find Your CDMO
- July 2026 — CDMO Opportunities And Threats Report
- ADC CDMO Selection For Small Biotech
- Implementing AI Solutions In GMP While Managing Risk
- Why Celcuity's REVTORPYK Creates A New Path For Precision Oncology
- Europe's ATMP Opportunity Still Requires Local Navigation
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Overcoming Analytical Bottlenecks In Oligonucleotide Drug Development With Automation
Growing oligonucleotide complexity is straining traditional analytical workflows. See how automated LC‑UV‑MS processing offers a scalable way to boost throughput and reduce manual effort.
-
Navigating Project Optimus And The Rapidly Changing Oncology Development Landscape
Project Optimus and adaptive trial designs are reshaping oncology development, improving patient outcomes, and streamlining approval pathways.
-
Balancing Protein A Resin Cost, Performance, And Productivity
Optimizing input parameters like DBC, flow rate, and resin durability is key to boosting productivity in downstream bioprocessing. Discover how to tailor resin choices to meet your specific process requirements.
-
Fully Automated Cell Culture Passaging And Expansion
Automating cell culture tasks can reduce human error and free scientists from labor-intensive routines. Discover how imaging and automated systems enhance accuracy and reproducibility in cell culture processes.
-
A Beginner's Guide To Sf9 Culture In Stirred-Tank Bioreactors
Learn about the workflow steps for Sf9 cell expansion, virus preparation, and protein production in stirred-tank bioreactors, including GFP expression.
-
Optimized Urine Liquid Biopsy Workflow
Urine-derived cell-free DNA is revolutionizing liquid biopsy research to offer a non-invasive, accessible tool for early disease detection, monitoring, and comprehensive diagnostics across oncology.
-
Assessing Particle Generation In A Single-Use Mixing System
Explore how particle levels remained stable during 24 hours of high-speed mixing, even under extreme temperatures, confirming a system’s suitability for final fill and other particulate-sensitive applications.
-
Expanding The Viscosity Limits Of Peristaltic Dosing
Discover how innovations in closed-loop control and mechanical design extend peristaltic dosing limits to 2000 cP, maintaining accuracy while preserving the advantages of sterile, disposable paths.
-
Scaling Manufacturing For Global Success
This collaboration demonstrates how a partnership-driven approach, combined with technical expertise, can deliver scalable, efficient, and reliable manufacturing solutions that support successful global commercialization.
-
A Study To Assess Organoid Size And Cell Count From 3D Image Analysis
Recent advancements in 3D patient-derived organoids (PDOs) offer improved predictive power over traditional 2D assays. Explore a patented bioprocess for PDO expansion that could revolutionize drug discovery, especially in oncology.
NEWSLETTER ARCHIVE
- 09.04.26 -- New Podcast Episodes: Fixing AAV Recovery, Cell Therapy Advances, Reimagining Solid Tumor Immunotherapy
- 09.04.26 -- The Blueprint For Viral Vector Manufacturing Success
- 09.04.26 -- Why Celcuity's REVTORPYK Creates A New Path For Precision Oncology
- 09.03.26 -- Real-Time Visibility Is Reshaping Outsourced Gene Therapy
- 09.03.26 -- How To Match CGT Manufacturing Models To Pipeline Needs With Legend Biotech
- Autoimmune CAR T Has Hit A Critical Moment. Are We Asking The Right Questions?
- Why Celcuity's REVTORPYK Creates A New Path For Precision Oncology
- In Vivo CAR T Needs More Than Better Cell Engineering
- Reimagining Solid Tumor Immunotherapy With SRC-3-Edited Tregs
- Building Antigen-Specific Immune Tolerance For Autoimmune Disease
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections